Last update 26 Apr 2025

MK-6213

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MK 6213
Target
NPC1L1
Action
inhibitors
Mechanism
NPC1L1 inhibitors(Niemann-Pick C1-like protein 1 inhibitors), Cholesterol absorption inhibitors
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic Disease
Active Indication-
Inactive Indication
AtherosclerosisHypercholesterolemiaPrimary hypercholesterolemia
Originator Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Organization-
Inactive Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.Merck GmbH
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with MK-6213
NCT00687271
/ CompletedPhase 2
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy, and Tolerability of MK-6213 Co-Administered With Atorvastatin in Patients With Primary Hypercholesterolemia
EUCTR2007-003684-41-BE
/ Not yet recruitingNot Applicable
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Dose-Ranging Study with Active-Controlled Long-Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in Patients with Primary Hypercholesterolemia orMixed Hyperlipidemia. - Hypercholesterolemia and hyperlipidemia dose ranging study.
100 Clinical Results associated with MK-6213
Login to view more data
100 Translational Medicine associated with MK-6213
Login to view more data
100 Patents (Medical) associated with MK-6213
Login to view more data
100 Deals associated with MK-6213
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Primary hypercholesterolemiaPhase 2-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Jun 2008
AtherosclerosisPhase 2-
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
-
HypercholesterolemiaPhase 2
United States
Merck GmbH
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT00687271 (6213-006, CTgov)
Phase 2
Primary hypercholesterolemia
334
(MK-6213 160 mg + Atorvastatin 20 mg)
cumqojmdpn(drxeimlptj) = fbumhougqh uxcorbohqx (dbjkxldxxm, vxxwgjxikl - pbnllaqtfv)
View more
-
01 Nov 2018
Atorvastatin calcium+Placebo for MK-6312 160 mg
(Atorvastatin 20 mg)
cumqojmdpn(drxeimlptj) = jdfmkjzbfi uxcorbohqx (dbjkxldxxm, cwutdmledf - hjcoudyiju)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free